BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
Home
» Medilink nets second $1B deal, out-licenses ADC to Roche
To read the full story,
subscribe
or
sign in
.
Medilink nets second $1B deal, out-licenses ADC to Roche
Jan. 9, 2024
By
Marian (YoonJee) Chu
No Comments
Three months out from its first $1 billion deal with Biontech SE for an antibody-drug conjugate (ADC), Suzhou, China-based Medilink Therapeutics Co. Ltd. clinched another potential $1 billion ADC deal, but this time with Roche Holding AG.
BioWorld Asia
Deals and M&A
License
Antibody-drug conjugate
Asia-Pacific
China
